The decision to restart blood-thinning medication following a subdural hematoma (SDH) is a complex clinical challenge, balancing the risks of recurrent bleeding against the potential for thromboembolic events. This delicate balance must consider factors such as the size and location of the hematoma, the patient’s neurological status, the reason for initial anticoagulation, and the individual’s risk factors for both bleeding and clotting.
Balancing the risks of recurrent intracranial hemorrhage with the risks of thromboembolism (such as stroke or pulmonary embolism) in patients with a history of SDH is crucial. Optimal management requires a multidisciplinary approach involving neurologists, hematologists, and other relevant specialists. Current guidelines and research aim to provide evidence-based recommendations to navigate this complex clinical scenario and improve patient outcomes. Historically, restarting this type of medication was approached with extreme caution, but evolving research has provided greater insight for personalized decision-making.
